Cystic Fibrosis

IWBCA
Feb 14
32 min read

Cystic fibrosis (CF) is an inherited condition caused by variants in the CFTR gene that disrupt the movement of salt and water in many organs. Thick, sticky mucus accumulates in the lungs, pancreas, sinuses, intestines, liver, and reproductive tract, leading to breathing problems, chronic infections, malabsorption, and undernutrition. In women, CF can also affect menstrual cycles, fertility, pregnancy, and bone health. Management relies on daily airway clearance, medications that thin mucus or improve CFTR function, pancreatic enzyme replacement, targeted nutritional support, and coordinated multidisciplinary care across the lifespan.

Overview

What is cystic fibrosis?

In healthy lungs, mucus is thin and slippery, allowing air to move freely while trapping and clearing germs. In cystic fibrosis, mucus becomes abnormally thick and sticky. It clogs the small airways, impairs breathing, and creates an environment conducive to bacterial and fungal growth. Repeated infections and inflammation gradually damage lung tissue and can lead to bronchiectasis, respiratory failure, and, in some cases, the need for lung transplantation.

The name “cystic fibrosis” reflects the characteristic changes in the pancreas. Thick secretions block the tiny ducts that carry digestive enzymes into the small intestine. Over time, this obstruction and inflammation lead to cyst formation and scarring in the pancreas. When enough tissue is damaged, the pancreas cannot release adequate enzymes for digestion, leading to exocrine pancreatic insufficiency with greasy stools, weight loss, and vitamin deficiencies. Many people also develop cystic fibrosis–related diabetes, which combines features of insulin deficiency and variable insulin resistance.

CF can involve other organs as well, including:

Liver and bile ducts can develop cholestasis, focal biliary cirrhosis, or portal hypertension.
Sinuses often develop chronic sinusitis and nasal polyps.
Intestines can be affected by meconium ileus in newborns or distal intestinal obstruction syndrome later in life.
Bones are vulnerable to low bone density and fractures, particularly in women with long-standing inflammation, steroid exposure, or nutritional deficits.

Reproductive health is a major consideration, and sex-specific patterns matter. In women and people assigned female at birth:

Thick cervical mucus can make it harder for sperm to pass through the cervix, contributing to subfertility, although many women with CF are still able to conceive.
Chronic undernutrition, low body weight, or severe illness can delay puberty, cause irregular periods, or lead to missed periods.
Vaginal and vulvar symptoms may be influenced by frequent antibiotics and altered microbiota.
Pregnancy places additional demands on the lungs, heart, and nutrition and requires close monitoring by both CF specialists and high-risk obstetric teams. CF-related diabetes, reduced lung function, and low weight can increase risks for preterm birth, growth restriction in the fetus, and maternal complications.
Hormonal changes across the menstrual cycle and during pregnancy can influence mucus thickness, lung symptoms, and blood sugar control.

At the cellular level, CF arises from changes in the CFTR gene, which provides instructions for the cystic fibrosis transmembrane conductance regulator protein. CFTR regulates the movement of chloride and bicarbonate ions across cell membranes in the airways, pancreas, sweat glands, and reproductive tract. When CFTR is absent or dysfunctional, chloride cannot exit cells effectively. Water movement follows chloride, so less water reaches the airway and duct surfaces. Mucus becomes dehydrated, dense, and difficult to clear, driving progressive organ damage.

Cystic fibrosis is present from birth and follows an autosomal recessive inheritance pattern. A child must inherit a CFTR variant from each biological parent to develop the disease. It is a lifelong condition that tends to worsen over time, although CFTR modulator therapies and modern supportive care have improved survival and quality of life, with growing numbers of women with CF reaching adulthood, pursuing careers, and starting families.

Categorization

Is there more than one type of cystic fibrosis?

Clinicians often describe cystic fibrosis in two broad patterns, based on the extent of organ involvement and the typicality of the presentation.

Classic CF usually appears in infancy or early childhood and involves multiple organ systems. Children often have persistent cough, wheezing, recurrent lung infections, poor weight gain despite a strong appetite, and bulky or greasy stools due to exocrine pancreatic insufficiency. Sweat chloride concentrations are typically clearly elevated on diagnostic testing. Without treatment, classic CF leads to progressive lung damage and significant nutritional compromise. With current therapies, many individuals with classic CF, including women, survive into middle adulthood and beyond, although they require intensive daily treatment and regular specialist follow-up.

In girls and women with classic CF, delayed puberty, late onset of menstruation, menstrual irregularities, and challenges achieving or maintaining a healthy weight are common. As they reach adulthood, discussions about fertility, contraception, and pregnancy planning become central parts of care. Many women with classic CF can conceive but need careful preconception assessment of lung function, nutritional status, and CF-related diabetes, along with close monitoring throughout pregnancy.

Atypical CF is a milder or more limited form in which symptoms may be subtle, involve only one or a few organs, or appear later in life. Individuals may have chronic sinusitis, recurrent bronchitis, episodic pancreatitis, male infertility due to congenital absence of the vas deferens, or intermittent respiratory symptoms without the full classic picture. Sweat chloride values can be borderline or only mildly elevated, and CFTR gene variants may retain partial function.

In women, atypical CF may present with long-standing respiratory or sinus complaints, unexplained pancreatitis, or unexplained subfertility or recurrent pregnancy loss before CF is considered. Because the manifestations can overlap with more common conditions, many women with atypical CF are diagnosed only after detailed CFTR genetic testing and sweat chloride evaluation prompted by persistent or clustered symptoms. Once identified, they benefit from tailored airway clearance, CFTR modulator therapy when eligible, pancreatic and nutritional support if needed, and reproductive counseling that accounts for both their own health and the risk of passing CFTR variants to future children.

Symptoms

What are the most common symptoms associated with cystic fibrosis?

Cystic fibrosis affects multiple organ systems. Symptoms often cluster around the lungs and sinuses, the digestive tract and nutrition, growth and bone health, and in older children and adults, endocrine and reproductive function. Patterns change with age. Some infants show problems in the first weeks of life, while others present later with subtle or organ-limited disease that only reveals its full pattern over time.

1. Classic Cystic Fibrosis

Classic CF usually involves significant lung disease, pancreatic insufficiency with malabsorption, and growth or weight concerns beginning in infancy or early childhood. Over time, persistent infection and inflammation in the airways and chronic digestive problems shape the overall course of illness and the pattern of symptoms in daily life.

Respiratory And Sinus Symptoms: Respiratory and sinus symptoms sit at the center of classic CF for many patients. Thick, sticky mucus blocks airways and sinus passages, trapping bacteria and interfering with normal clearance. This leads to repeated infections, chronic cough, and structural changes in the lungs and sinuses that may progress even when symptoms temporarily improve between infections.

Frequent Lung Infections: Recurrent episodes of bronchitis or pneumonia often require repeated courses of antibiotics and sometimes hospital care. Infections may appear to clear, then return within weeks or months. Over time, this cycle can lead to chronic airway damage, bronchiectasis, and a gradual decline in lung function.

Persistent Cough: A long-standing cough, usually wet or productive with thick mucus, often lingers even between acute infections. Cough may worsen with respiratory viruses, exercise, exposure to irritants, or lying down at night, and can disturb sleep for both the person with CF and their family.

Trouble Breathing: Shortness of breath with activity, reduced exercise tolerance compared with peers, and a sensation of chest tightness are common. In more advanced disease, breathlessness can occur with minimal exertion or at rest, and daily tasks such as climbing stairs, showering, or dressing may feel increasingly difficult.

Frequent Wheezing: Whistling or musical breathing sounds reflect narrowed or mucus-filled airways. Wheezing in CF is often labeled as asthma but may respond only partially to standard inhalers, because the underlying problem is thick mucus and chronic infection in addition to airway narrowing.

Frequent Sinus Infections: Chronic nasal congestion, thick nasal discharge, facial pressure or headache, and recurrent sinusitis are frequent. Many people develop nasal polyps that further obstruct airflow and reduce the sense of smell, contributing to ongoing discomfort and recurrent infections.

Chronic Fatigue: Persistent tiredness is common and can stem from the constant work of breathing, nocturnal coughing, disrupted sleep, and the metabolic demands of chronic infection and inflammation. Fatigue can limit school, work, and social activities, even when lung function tests appear stable.

Digestive and Nutritional Symptoms

Digestive and nutritional problems arise when thick secretions block ducts in the pancreas and prevent digestive enzymes from reaching the intestine. As a result, the body struggles to absorb fat, protein, and fat-soluble vitamins, even when appetite is strong and food intake looks adequate.

Loose or Oily Stools: Bulky, pale, greasy, or foul-smelling stools that may float or leave an oily film in the toilet reflect poor absorption of fat. Families may notice frequent, large-volume stools and difficulty flushing. These stool changes are a key clue to pancreatic insufficiency in CF.
Abdominal Symptoms: Bloating, cramping, and excess gas after meals are common, especially when pancreatic enzyme replacement is inadequate or missed. Some people experience constipation, while others develop partial or complete bowel blockage. Meconium ileus in newborns and distal intestinal obstruction syndrome in older children and adults are well-recognized CF-related bowel complications.
Slow Growth and Low Weight: Height and weight may fall behind peers despite strong appetite and apparently generous intake. Growth charts can show a gradual shift to lower percentiles, because the body is burning more calories fighting infection while absorbing fewer nutrients. This pattern can appear long before a diagnosis is made.
Failure to Thrive in Infants and Young Children: Infants may struggle to gain expected weight or length despite frequent feeds and normal or strong appetite. They may have frequent stools, irritability, or lethargy. In these cases, the limiting factor is absorption rather than interest in feeding, and CF should be considered as a possible explanation.
Signs of Vitamin and Mineral Deficiency: Easy bruising, dry or thinning hair, brittle nails, muscle cramps, bone pain, or frequent infections can signal low levels of fat-soluble vitamins A, D, E, and K and other micronutrients. These deficiencies reflect long-standing malabsorption and can worsen bone health and immune function if not addressed.
Hepatic, Endocrine, and Bone-Related Symptoms: As survival improves and people with CF live longer, complications involving the liver, endocrine system, and bones are recognized more often. These problems may evolve gradually and require active monitoring in both pediatric and adult CF care.
Liver and Biliary Symptoms: Some individuals develop CF-related liver disease, with enlarged liver, right upper abdominal discomfort, jaundice, or unexplained abnormalities in liver blood tests. Thickened secretions and altered bile flow can lead to focal biliary cirrhosis or broader liver involvement over time.

CF-Related Diabetes (CFRD)

CF-related diabetes combines features of type 1 and type 2 diabetes and often appears in adolescence or adulthood. Symptoms can include increased thirst, frequent urination, unexplained weight loss, and sometimes an unexpected decline in lung function or increased infection frequency, even before obvious high blood sugar is detected.

Low Bone Density and Fractures: Reduced bone mineral density and osteoporosis can lead to back pain, rib pain, or fractures after minimal trauma. Contributing factors include vitamin D deficiency, chronic inflammation, steroid exposure, low body weight, and reduced physical activity. Bone health surveillance is an important part of long-term CF care.
Other Characteristic Findings: Some physical signs are highly suggestive of CF and can provide important clues in infants, children, and adults whose other symptoms seem unexplained or only partly explained by common conditions.
Salty-Tasting Skin: Caregivers may notice that a baby’s or child’s skin tastes unusually salty when kissed, or see fine salt crystals on the skin after sweating. This reflects high salt content in sweat due to abnormal chloride transport in the sweat glands and is a classic clue that often prompts sweat testing.
Digital Clubbing: Rounding and enlargement of the fingertips and nails develop gradually in many people with long-standing lung disease. Clubbing signals chronic structural damage and altered oxygenation in the lungs and should prompt evaluation for CF or other causes of chronic lung disease if not yet diagnosed.
Heat and Dehydration Symptoms: Headache, dizziness, nausea, muscle cramps, or episodes of heat exhaustion or heatstroke during hot weather or exercise can occur because people with CF lose large amounts of salt and fluid in sweat. These episodes may be more frequent than in peers and can be a presenting feature in undiagnosed individuals.
Reproductive and Sex-Specific Symptoms: Reproductive effects of CF vary by sex and age. They can influence puberty timing, menstrual patterns, and fertility, even when respiratory and digestive symptoms are relatively mild.

Women and People Assigned Female At Birth: Delayed onset of menstruation, irregular or absent periods in the setting of low weight or chronic illness, and cyclic worsening of respiratory or gastrointestinal symptoms around menses may occur. Later in life, difficulty conceiving can arise from thick cervical mucus and overall health status, even when ovulation is preserved.

Men And People Assigned Male At Birth: Infertility is common due to congenital bilateral absence of the vas deferens, which prevents sperm from reaching the ejaculate. Sexual development may appear normal, but semen analyses show very low or absent sperm counts. In some individuals, this fertility issue may be the feature that ultimately leads to CF evaluation.

Across all ages, combinations of chronic respiratory symptoms, digestive and nutritional problems, growth or weight concerns, and characteristic signs such as salty skin or clubbing should prompt evaluation for cystic fibrosis, especially when standard treatments for more common diagnoses have been only partially effective.

Atypical Cystic Fibrosis Symptoms

How can atypical cystic fibrosis present?

People with atypical CF have CFTR gene variants that preserve partial protein function. Symptoms may be milder, affect only one or a few organs, or appear later in life. Instead of the full classic picture, these individuals often show a fragmented pattern of problems that resemble more common conditions, which can delay recognition.

Organ-Limited or Milder Respiratory Disease: Some individuals present with chronic sinus or lung problems but lack obvious digestive or growth concerns. They may be treated repeatedly for “refractory sinusitis,” “asthma,” or “recurrent bronchitis” before CF is considered, especially if symptoms begin in adolescence or adulthood.
Chronic Sinusitis: Long-standing sinus congestion, facial pain or pressure, and recurrent sinus infections that persist despite standard medical and sometimes surgical treatment are common. Thick secretions and impaired mucociliary clearance in the sinuses are often key components of atypical CF.
Nasal Polyps: Soft growths in the nose or sinuses can cause obstruction, recurrent infections, or a reduced sense of smell. When nasal polyps occur in children or young adults, especially in combination with chronic sinusitis, CF should be on the differential diagnosis list.
Recurrent Bronchitis or Milder Lung Symptoms: Less severe but repeated chest infections, chronic cough, or unexplained wheezing may occur without the full spectrum of classic CF. Lung function may remain near normal for years, which can make the CF connection easy to overlook.
Pancreatitis: Repeated episodes of inflammation in the pancreas can cause upper abdominal pain, nausea, and vomiting. In atypical CF, pancreatitis may appear in people who do not have obvious chronic lung disease or malabsorption. CF evaluation is particularly important in those with recurrent or unexplained pancreatitis at a young age.
Diarrhea or Intermittent Loose Stools: Digestive symptoms may come and go, with intermittent loose stools, bloating, and abdominal discomfort. These features can be mistaken for irritable bowel syndrome or food intolerance, especially if growth and weight remain within normal ranges.
Unintended Weight Loss or Difficulty Maintaining Weight: Subtle signs of malabsorption or increased energy needs can appear as difficulty gaining or maintaining weight despite apparently adequate intake. This may be more noticeable during times of illness or increased activity.
Dehydration or Heat-Related Illness: Episodes of dehydration, heat exhaustion, or heatstroke during hot weather or exercise reflect excessive salt loss in sweat, similar to classic CF. These events may be recurrent and more severe than expected for the level of heat exposure.
Fertility Problems: In adults, unexplained subfertility, recurrent pregnancy loss, or azoospermia in men can occasionally be part of an atypical CF pattern, particularly when combined with respiratory, sinus, or pancreatic symptoms. In these settings, CFTR testing may clarify the diagnosis.

Because atypical CF mimics more common conditions, people are sometimes not diagnosed until adolescence or adulthood, when the pattern of recurrent or multi-system problems becomes easier to recognize. A high index of suspicion, combined with sweat testing and CFTR genetic analysis, is critical when these fragmented symptom clusters persist or fail to respond fully to standard care.

Causes

What are the most common causes of cystic fibrosis?

Cystic fibrosis is caused by disease-causing changes, often called variants or mutations, in the CFTR gene. The CFTR gene provides instructions for making the cystic fibrosis transmembrane conductance regulator protein. This protein sits in the outer membrane of certain cells and functions as an ion channel. CFTR dysfunction alters salt and water movement across epithelial surfaces in the airways, pancreas, intestines, sweat glands, and reproductive tract. The result is thick, sticky secretions, chronic infection and inflammation, and progressive organ damage.

CFTR Gene and Protein Function: The CFTR gene encodes the cystic fibrosis transmembrane conductance regulator protein. This protein spans the cell membrane and acts as a regulated pathway for specific ions. It is found in many epithelial tissues, including those that line the lungs and sinuses, pancreatic ducts, bile ducts, the intestinal tract, sweat glands, and parts of the reproductive system.
CFTR As An Ion Channel: CFTR forms a channel that mainly allows chloride ions to move out of cells. Through its effects on chloride, CFTR also influences bicarbonate transport. Chloride carries a negative electrical charge and plays a central role in maintaining salt and water balance on epithelial surfaces. When CFTR works properly, controlled movement of chloride helps keep airway and duct surfaces well hydrated and electrically balanced.
Role In Mucus Hydration: When chloride moves out of the cell through CFTR, water follows the osmotic gradient into the mucus layer at the cell surface. This water flow keeps secretions thin and slippery. In the airways, this allows cilia to move mucus along and clear inhaled particles and microorganisms. In the pancreas and intestines, it keeps digestive juices flowing and prevents thick plugs from blocking ducts.
Effects of CFTR Variants on Protein Production and Function: In cystic fibrosis, CFTR variants interfere with different steps in the life cycle of the protein. Some changes prevent CFTR from being made at all. Others cause the protein to misfold and be degraded inside the cell. Some reduce the number of channels that reach the cell surface. Others allow CFTR to reach the membrane but disrupt the opening and closing of the channel or reduce how well ions flow through it. All of these mechanisms decrease chloride movement, reduce water delivery to the mucus layer, and lead to thick, sticky secretions that are difficult to clear.

Functional Classes of CFTR Variants

Researchers group CFTR variants into functional classes, often described as classes I through VI, based on the main defect they cause in the protein. Some variants result in no CFTR protein being produced. Some produce a shortened or misfolded protein that is degraded before it reaches the cell surface. Some allow the protein to reach the surface but interfere with the channel’s opening and closing. Others reduce the stability or number of channels at the membrane or limit how well ions pass through the pore. These differences help explain why some people have severe, classic multi-organ CF and others have milder or organ-limited disease.

Genetic Inheritance Pattern: Cystic fibrosis follows an autosomal recessive inheritance pattern. A person must inherit two disease-causing CFTR variants, one from each biological parent, to develop CF. Parents who carry one CFTR variant usually do not have symptoms and are referred to as carriers. When both parents are carriers, each pregnancy has a fixed chance that the child will have CF, be a carrier, or inherit no CFTR variants. Many families have no known history of CF before a child is diagnosed, because carrier status is silent and common in the general population.
Modifier Genes and Environmental Influences: The primary cause of cystic fibrosis is always CFTR gene variation. However, other genes and environmental factors can influence how severe the disease becomes. Differences in immune response, antioxidant systems, and mucus properties, as well as exposures such as tobacco smoke, air pollution, nutrition, and access to treatment, can all modify the course of illness. These factors do not cause CF in the absence of CFTR variants, but they help determine how early symptoms appear, which organs are most affected, and how rapidly complications progress.
Implications for Treatment: Understanding how specific CFTR variants affect the protein guides the use of CFTR modulator medications. These drugs are designed to improve the amount or function of CFTR at the cell surface for particular defect types. People with variants that fit certain functional classes may benefit from modulators that correct misfolding, enhance channel gating, increase stability at the membrane, or combine these effects, while others still require primarily symptomatic and supportive care.

Classification

How are CFTR mutations classified?

CFTR gene variants are grouped into functional classes based on how they disrupt the CFTR protein. These classes help explain why disease severity varies from person to person and why some respond well to specific CFTR modulator therapies while others do not. Although the classification is a simplification and some variants fit more than one category, it provides a useful framework for understanding patterns of organ involvement and guiding treatment decisions.

Class I Defective Protein Production: Class I variants lead to little or no CFTR protein being produced. The genetic change often introduces a premature stop signal or severely abnormal instructions, so the cell cannot assemble a full-length protein. Because functional CFTR never reaches the cell surface, chloride transport is profoundly reduced, and individuals typically develop a classic, multi-organ CF phenotype with early and significant lung, pancreatic, and nutritional involvement.

Class II Defective Protein Processing and Trafficking: Class II variants allow CFTR protein to be made but cause it to misfold during processing. Misfolded CFTR fails quality-control checks inside the cell and is targeted for degradation before reaching the cell surface. The most common global CF variant, F508del, falls into this class. The result is markedly reduced CFTR at the cell membrane and severe impairment of chloride transport, often associated with classic CF features and early-onset disease.

Class III Defective Channel Regulation: Class III variants, sometimes called gating variants, allow CFTR to reach the cell surface but disrupt the opening and closing of the channel. The protein sits in the membrane, yet the gate at the end of the channel does not respond properly to regulatory signals. Chloride movement remains severely reduced even though CFTR is present, leading to significant functional loss that resembles the clinical severity seen in Class I and Class II disease.

Class IV Defective Conductance: Class IV variants form a channel in the membrane and permit the gate to open, but the pore conducts chloride poorly. Ion flow is reduced rather than completely blocked, so residual CFTR function is higher than in Classes I through III. People with Class IV variants may have milder or organ-limited disease, such as later-onset lung involvement, pancreatic sufficiency, or isolated sinus or reproductive issues, although this pattern can vary.

Class V Reduced Protein Synthesis: Class V variants produce CFTR that is structurally normal and functional but in reduced quantities. Mechanisms such as altered splicing or regulatory changes decrease the amount of protein made, leaving fewer channels in the membrane. Residual CFTR activity is greater than in the more severe classes, which often translates into milder clinical features, later onset of symptoms, or disease limited to certain organs.

Class VI Increased Turnover at the Cell Surface: Class VI variants allow CFTR to reach the plasma membrane and function, but the protein is unstable and is removed too quickly. The accelerated turnover reduces the number of working channels on the cell surface over time. This pattern can lead to variable disease severity and may overlap clinically with Class IV and Class V presentations, depending on how much CFTR activity is preserved.

These functional classes help explain why some individuals develop severe early-onset lung and pancreatic disease, while others present later in life with bronchiectasis, recurrent pancreatitis, male infertility, or other organ-limited manifestations. They are also central to the choice of CFTR modulators, since different drugs are designed to correct specific defects such as misfolding, gating failure, or reduced surface stability. In practice, many CFTR variants show features of more than one class, and treatment decisions increasingly combine this framework with real-world responses to modulators and detailed genetic information.

Complications

What are the most common complications of cystic fibrosis?

Cystic fibrosis can affect nearly every system that relies on normal mucus clearance, digestion, and salt balance. Complications tend to build over time as chronic infection, inflammation, malabsorption, and organ damage accumulate. The main complications include the following.

Infections: Thick, sticky mucus traps bacteria and fungi in the airways, making effective clearance difficult. This leads to recurrent, often chronic, lung infections, particularly with organisms such as Staphylococcus aureus and Pseudomonas aeruginosa. Over time, repeated infections and persistent inflammation can lead to bronchiectasis, progressive loss of lung function, hemoptysis (coughing up blood), respiratory failure, and, in some cases, the need for long-term oxygen therapy or lung transplantation. Sinus infections and chronic sinusitis are also common and can significantly affect quality of life.

Congenital Bilateral Absence Of The Vas Deferens (CBAVD): In many males with cystic fibrosis, the vas deferens (the ducts that carry sperm from the testes) do not form properly before birth. This is called congenital bilateral absence of the vas deferens. These individuals typically produce sperm but have no pathway for sperm to reach the ejaculate, resulting in obstructive azoospermia and infertility. Hormone levels, sexual function, and libido are often normal. Fertility options usually involve assisted reproductive techniques such as sperm retrieval directly from the testes or epididymis, combined with in vitro fertilization or intracytoplasmic sperm injection.

Diabetes (Cystic Fibrosis–Related Diabetes): Long-standing damage and scarring in the pancreas can destroy insulin-producing cells and lead to cystic fibrosis–related diabetes (CFRD). CFRD has features of both insulin deficiency and insulin resistance and is distinct from typical Type 1 or Type 2 diabetes. It often presents in adolescence or adulthood and may initially present with unexplained weight loss, increased thirst and urination, or a decline in lung function. CFRD can worsen nutritional status, accelerate lung decline, and increase the risk of classic diabetes complications if not recognized and treated. Regular screening and early insulin therapy are key parts of CF care.

Malnutrition: Thick secretions and blocked pancreatic ducts often lead to exocrine pancreatic insufficiency, in which digestive enzymes cannot reach the small intestine. As a result, fats, proteins, and fat-soluble vitamins are poorly absorbed. Even with a strong appetite and high-calorie intake, people with CF can struggle to maintain weight and muscle mass. Malnutrition contributes to poor growth in children, delayed puberty, reduced exercise tolerance, impaired immune function, delayed wound healing, and overall frailty. Pancreatic enzyme replacement and targeted nutritional support are essential to prevent and correct these deficits.

Osteopenia and Osteoporosis: Bone health is a major long-term concern in CF. A combination of factors contributes to low bone mineral density, including chronic inflammation, vitamin D and K deficiency, reduced calcium absorption, low body weight, limited weight-bearing activity, and the use of glucocorticoids in some individuals. This can lead to osteopenia and osteoporosis at a younger age than in the general population, increasing the risk of vertebral and rib fractures, height loss, and chronic pain. Preventive strategies include adequate nutrition, vitamin and mineral supplementation, regular bone density screening, and treatment when bone loss is detected.

Pregnancy Complications: In people with CF who become pregnant, the condition can affect both maternal and fetal outcomes. Poor nutritional status, reduced lung function, CF-related diabetes, and chronic infections can increase the risk of complications such as preterm birth, low birth weight, impaired fetal growth, and maternal respiratory decompensation. Some medications used to manage CF may need adjustment during pregnancy. With careful pre-pregnancy assessment, close monitoring by a multidisciplinary team (including CF specialists and high-risk obstetrics), and aggressive support for nutrition and lung health, many individuals with CF can have successful pregnancies, but the risks are higher than in the general population and require thoughtful planning and follow-up.

Diagnosis and Testing

How is cystic fibrosis diagnosed?

Cystic fibrosis is diagnosed by demonstrating abnormal CFTR function in a person with either a positive newborn screen, characteristic clinical features, or a suggestive family history. In modern practice, most diagnoses begin with newborn screening and are confirmed in a cystic fibrosis center with sweat testing and CFTR genetic analysis. In older children and adults, diagnosis is often prompted by a pattern of respiratory, gastrointestinal, or reproductive symptoms that cannot be fully explained by other conditions.

Newborn screening programs use a heel-prick blood sample to measure immunoreactive trypsinogen (IRT), a pancreatic enzyme precursor that leaks into the bloodstream when the pancreas is stressed. Many programs repeat IRT and/or add targeted CFTR DNA testing to improve accuracy. An abnormal newborn screening result indicates an increased risk and always requires confirmatory testing; it does not, by itself, establish a diagnosis of cystic fibrosis. Some infants with CF have normal or only mildly elevated IRT, and adults diagnosed later in life were often born before universal screening existed.

Once screening or symptoms raise suspicion, the diagnostic workup centers on sweat chloride testing, CFTR genetic analysis, and, in selected cases, functional measurements of ion transport, supported by imaging and physiological testing of lungs and pancreas.

Sweat Chloride Test

The quantitative pilocarpine iontophoresis sweat test is the reference standard for confirming cystic fibrosis. A small area of skin, usually on the forearm, is stimulated to produce sweat, which is then collected and analyzed for chloride concentration.

Typical interpretation in specialty centers follows these thresholds:

Less than or equal to 29 mmol/L: cystic fibrosis is unlikely at any age
30 to 59 mmol/L: intermediate range; CF is possible, and further evaluation is required
60 mmol/L or higher: consistent with cystic fibrosis in the appropriate clinical context

In classic CF, sweat chloride values are usually clearly elevated. In atypical CF or CFTR-related disorders, values may be intermediate or occasionally near normal; therefore, results must always be interpreted in the context of genetics and clinical features.

CFTR Genetic Testing

CFTR genotyping examines blood or cheek-swab DNA for variants known to affect CFTR function. Standard panels focus on the most common disease-causing variants; however, full gene sequencing and deletion/duplication analysis are often required when suspicion remains high, and panel testing is nondiagnostic.

Key points for readers:

Identification of two disease-causing CFTR variants in a person with a positive sweat test or compatible clinical picture is strong evidence for cystic fibrosis.
Detection of one variant indicates carrier status and does not explain symptoms on its own.
Some CFTR variants have variable or uncertain clinical impact; in these cases, functional testing (NPD, ICM) and longitudinal follow-up help clarify whether the individual has classic CF, a milder CFTR-related disorder, or an unrelated condition.

Supporting Respiratory and Sinus Evaluation

Chest and Sinus Imaging: Chest radiographs and high-resolution CT scans can show structural lung changes typical of chronic CF airway disease, including bronchiectasis, mucus plugging, hyperinflation, and parenchymal scarring. Sinus imaging often reveals mucosal thickening, sinus opacification, or nasal polyps. These findings support the diagnosis and provide a baseline for monitoring progression, although they are not specific enough to diagnose CF on their own.
Pulmonary Function Tests: Spirometry and related pulmonary function tests measure airflow and lung volumes. In cystic fibrosis, results commonly show obstructive physiology, air trapping, and, in advanced disease, reduced lung capacity. Abnormalities on pulmonary function testing help quantify the impact of CF on lung performance and guide treatment intensity, but they do not distinguish CF from other causes of chronic airway obstruction without additional context.
Sputum Culture: Microbiological analysis of expectorated sputum or lower airway samples identifies organisms colonizing or infecting the respiratory tract. Chronic or recurrent infections with pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus, or Burkholderia species are characteristic of CF lung disease and inform antibiotic selection and infection-control practices. The presence of these organisms is supportive but not diagnostic by itself.

Pancreatic and Gastrointestinal Evaluation

Pancreatic Exocrine Function Testing: Because cystic fibrosis frequently causes exocrine pancreatic insufficiency, assessment of pancreatic enzyme output is important. Noninvasive fecal elastase-1 measurement is widely used; low fecal elastase suggests significant exocrine insufficiency. Clinical indicators include steatorrhea, weight loss, and failure to thrive. Imaging may show pancreatic atrophy, fatty replacement, or cystic changes in long-standing disease. These findings strengthen the classification of diabetes, malnutrition, and intestinal symptoms as CF-related rather than coincidental.

Specialized Functional CFTR Tests

In complex or borderline cases, direct measurements of ion transport can clarify the functional impact of CFTR variants when sweat chloride and genotyping are inconclusive.

Nasal Potential Difference (NPD): NPD measures the electrical potential across the nasal epithelium, which reflects ion movement through CFTR and other channels in the airway surface. By perfusing the nasal mucosa with specific solutions and recording voltage changes, clinicians can characterize chloride and sodium transport. Individuals with cystic fibrosis typically show a distinctive pattern of elevated baseline potential and blunted chloride-dependent responses. NPD is available in specialized centers and is reserved for diagnostic dilemmas, such as suspected atypical CF with borderline sweat tests.
Intestinal Current Measurement (ICM): ICM evaluates CFTR-dependent chloride secretion in rectal epithelium. A small rectal biopsy is mounted in a Ussing chamber, and ion currents are measured under controlled conditions. Reduced or absent CFTR-mediated currents are highly indicative of cystic fibrosis. Like NPD, ICM is performed in a limited number of reference laboratories and is primarily used to resolve uncertainty in individuals with atypical clinical presentations or ambiguous genetic findings.

In contemporary practice, most diagnoses are established through a combination of newborn screening, sweat chloride testing, and CFTR genetic analysis, with imaging, lung function testing, microbiology, and pancreatic assessment used to define disease burden. NPD and ICM provide additional clarity in a minority of cases where standard tests do not fully align with the clinical picture.

Management and Treatment

How do you treat cystic fibrosis?

Cystic fibrosis has no cure, so treatment focuses on correcting or compensating for CFTR dysfunction, preserving lung and digestive function, preventing complications, and supporting quality of life across the lifespan. Care is usually coordinated through a specialized cystic fibrosis center and tailored to age, CFTR genotype, organ involvement, and response to CFTR modulators. Most people follow a structured regimen that evolves over time as their clinical status and available therapies change.

Core Treatment Pillars: Treatment in CF rests on several interlocking pillars that work together rather than as isolated interventions. These include daily clearance of airway mucus, CFTR modulator therapy for eligible genotypes, targeted medications for infection control and digestion, intensive nutritional support and salt replacement, and timely use of procedures and surgery, including transplantation in advanced disease. The relative weight of each pillar shifts as children grow, adults age, and CFTR modulators reshape the natural history of the condition.

Airway Clearance Techniques: Clearing thick, infected mucus from the lungs remains central in CF care, even in the era of CFTR modulators. The aim is to mobilize secretions from small airways, move them toward larger airways, and expel them in a controlled way that protects the lungs and reduces the risk of infection. Airway clearance is typically performed at least once or twice daily and intensified during exacerbations, with techniques individualized to age, lung function, and personal preference.

Specialized Coughing and Breathing Techniques: Respiratory physiotherapists teach structured breathing programs such as the active cycle of breathing, huff coughing, and other maneuvers that alternate deep breaths, breath holds, and forced exhalations. These strategies help open narrowed airways, move air behind mucus plugs, and make coughing more productive while minimizing exhaustion, chest discomfort, and vomiting. Families often learn to adapt these techniques as children grow and as disease severity changes.

Positive Expiratory Pressure Devices: Positive expiratory pressure devices, used with a mouthpiece or mask, create resistance during exhalation so that the person must exhale against a small back pressure. This splints the airways open, drives air behind mucus, and improves clearance. Oscillating PEP devices such as Flutter, Acapella, Aerobika, and RC-Cornet add high-frequency vibrations that further loosen secretions and can be combined with breathing exercises for greater effect.

High-Frequency Chest Wall Oscillation Vests: High-frequency chest wall oscillation vests connect to a compressor that rapidly inflates and deflates the vest, producing rhythmic chest compressions. These oscillations dislodge mucus from airway walls throughout the lung fields and can be particularly useful for people who cannot perform or sustain manual percussion or intensive breathing exercises. Vests are often incorporated into daily routines at home and can be adjusted in frequency and intensity to match comfort and response.

Postural Drainage and Manual Percussion: Postural drainage positions the body so gravity assists mucus drainage from targeted lung segments, while a caregiver or therapist uses cupped hands to clap on the chest and back to loosen secretions. This more traditional method is often combined with breathing and coughing techniques and remains valuable where devices are unavailable or as part of a mixed regimen. It requires training and time but can be highly effective when done regularly.

Adjunct Inhaled Therapies For Airway Clearance: Short-acting bronchodilators, inhaled hypertonic saline, and inhaled dornase alfa are frequently given in a specific order before or during airway clearance sessions. Bronchodilators relax airway smooth muscle, hypertonic saline draws water into mucus to rehydrate and thin secretions, and dornase alfa breaks down extracellular DNA in sputum to reduce viscosity. These therapies increase the effectiveness of airway clearance techniques and can reduce exacerbations when used consistently.

CFTR Modulator Therapy: CFTR modulators directly target the underlying protein defect in CF rather than focusing only on symptoms. These small molecules improve the amount or function of CFTR at the cell surface for specific classes of gene variants. For many individuals, modulators have transformed outcomes, increasing lung function, improving weight and nutritional status, reducing pulmonary exacerbations, and decreasing the daily treatment burden, although airway clearance usually continues in some form.

Current CFTR Modulator Regimens: Current regimens include ivacaftor alone for gating and some residual function variants, combination products such as lumacaftor or tezacaftor paired with ivacaftor for selected F508del genotypes, and triple-combination therapy with elexacaftor, tezacaftor, and ivacaftor for people with at least one F508del allele or other responsive variants. These triple combinations are now recommended for a broad age range in many regions, subject to regulatory approvals and local policies.

Eligibility and Monitoring Considerations: Eligibility for CFTR modulators depends on CFTR genotype, age, regulatory labeling, and local coverage or reimbursement policies. Modulators are usually taken long-term with fat-containing meals to optimize absorption and require periodic monitoring of liver enzymes, blood pressure, mood, and possible drug interactions. Not everyone qualifies for or tolerates these therapies, and clinical response can vary, so treatment plans are adjusted based on objective measures and patient-reported changes.

Limitations and Unequal Access: A proportion of people with rare or non-responsive variants still rely entirely on traditional symptomatic management because no approved modulator targets their specific defect. Others may be eligible but lack access due to cost or regulatory limitations. For these individuals, optimizing airway clearance, infection control, nutrition, and complication management remains crucial while research into broader modulator coverage and alternative strategies continues.

Alongside CFTR modulators and airway clearance, most people with CF receive a combination of medications targeting infection, mucus properties, airway tone, inflammation, and digestive function. These therapies are adjusted frequently based on sputum cultures, lung function, symptoms, and treatment side effects, and they remain essential even when modulator therapy is in place.

Antibiotic Strategies for Infection Control: Antibiotic regimens include oral, inhaled, and intravenous agents chosen based on sputum culture results and resistance patterns. Chronic suppression of organisms such as Pseudomonas aeruginosa and rapid, aggressive treatment of pulmonary exacerbations are central to preserving lung function. Inhaled antibiotics provide high local concentrations with fewer systemic side effects, while intravenous courses are reserved for more severe or refractory infections.

Bronchodilators and Airway Tone Management: Short-acting beta-agonists are commonly used before airway clearance to relax airway smooth muscle and improve airflow to mucus-plugged regions, making clearance more efficient. Long-acting bronchodilators may be added for individuals with significant reversible obstruction or overlapping asthma, and are tailored to spirometry results and symptom patterns.

Mucus-Hydrating and Mucolytic Agents: Inhaled hypertonic saline increases water content in airway secretions, while dornase alfa enzymatically breaks down DNA from inflammatory cells in sputum, lowering viscosity and making mucus easier to mobilize. Inhaled mannitol is an additional option for selected adults. These agents are often used in combination and have been shown to improve lung function and reduce exacerbations when integrated into consistent daily routines.

Anti-Inflammatory Approaches: Long-term macrolide therapy, such as azithromycin, is used in selected patients to reduce neutrophilic airway inflammation and exacerbation frequency, independent of its antimicrobial effects. Inhaled or systemic corticosteroids may be prescribed when coexisting asthma or allergic bronchopulmonary aspergillosis is present, but they are not standard maintenance therapy for all people with CF because of potential side effects.

Pancreatic and Gastrointestinal Therapies: Enteric-coated pancreatic enzyme replacement is taken with meals and snacks to support digestion of fat and protein and prevent steatorrhea, abdominal symptoms, and weight loss. Acid suppression with proton pump inhibitors or H2 blockers is often co-prescribed to enhance enzyme activity in the small intestine. Additional medications such as stool softeners, osmotic laxatives, or more intensive regimens help prevent and treat distal intestinal obstruction and chronic constipation, both of which are common and potentially serious.

Endocrine and Metabolic Treatments: CF-related diabetes is generally managed with insulin regimens tailored to fluctuating appetite, variable intake, and the impact of illness on blood glucose. Bone-protective therapies, including vitamin D optimization, calcium supplementation, and in some cases pharmacologic agents for osteoporosis, are introduced for individuals with low bone density or fractures. Regular surveillance for endocrine complications guides the timing and intensity of these interventions.

Infection Control and Preventive Care: Vaccination against influenza, pneumococcus, and other vaccine-preventable infections is integrated into CF care to reduce respiratory infection burden. Rigorous infection-control practices in clinics and hospitals, including segregation policies and careful cleaning protocols, aim to prevent cross-infection with resistant organisms. Early recognition and treatment of exacerbations are emphasized to prevent stepwise loss of lung function.
Nutrition and Dietary Management: Nutritional care is a core component of CF management, closely linked to respiratory outcomes. Good nutritional status correlates with better lung function, fewer hospitalizations, and improved survival. Dietitians with CF expertise work with families and adults to create individualized plans that respond to changing growth patterns, infection burden, and modulator use.
High-Energy Intake Requirements: Many people with CF require substantially higher daily caloric intake than peers without CF, often in the range of 110 to 200 percent of typical energy requirements for age and sex. High-calorie meals, frequent snacks, calorie-dense oral supplements, and, when needed, enteral tube feeding are used to achieve and maintain target weight and growth trajectories, especially in childhood and adolescence.

Adequate Fat and Protein Intake: Dietary plans are typically rich in fat and protein, with pancreatic enzyme dosing carefully matched to meal composition. This approach maximizes energy density, supports muscle mass, and helps sustain a healthy body mass index. Consistent enzyme use allows people to take advantage of high-fat foods without excessive gastrointestinal symptoms.

Micronutrient Supplementation and Monitoring: Routine supplementation of fat-soluble vitamins A, D, E, and K is standard in pancreatic-insufficient CF, along with attention to calcium, iron, zinc, and essential fatty acids. Regular laboratory monitoring guides dose adjustments, because requirements shift with age, infection intensity, and changes introduced by CFTR modulators. Correcting deficiencies supports bone health, immunity, and overall well-being.
Salt and Fluid Replacement Strategies: Because people with CF lose large amounts of sodium and chloride in sweat, extra dietary salt and careful hydration are usually recommended, especially in hot weather, during exercise, or with fever. Individualized guidance from the CF care team balances the need to prevent dehydration and heat illness against the risks of excessive salt intake in specific clinical contexts.

Nutrition on the Era of CFTR Modulators: Highly effective modulator therapy has changed growth trajectories and body composition for many individuals, sometimes shifting the challenge from undernutrition toward weight management and cardiometabolic risk. Nutrition plans now must address both traditional concerns about malabsorption and emerging patterns such as overweight or obesity in a subset of treated people. Ongoing review with dietitians helps keep plans aligned with current health priorities.
Surgery and Advanced Interventions: Surgical and procedural interventions are reserved for specific complications or advanced organ failure that persists despite optimized medical therapy. These interventions are usually planned and delivered at specialized centers with expertise in CF.

Sinus and Upper Airway Surgery: Functional endoscopic sinus surgery can relieve obstruction from nasal polyps and chronic sinus disease, improve nasal breathing, and reduce infection burden for carefully selected patients. Postoperative care still requires ongoing medical therapy and airway clearance, but surgery can improve quality of life when sinus disease is severe.

Gastrointestinal and Nutritional Procedures: Newborns with meconium ileus and older individuals with recurrent distal intestinal obstruction or complications such as perforation may require emergency or elective gastrointestinal surgery. Placement of gastrostomy tubes for long-term enteral nutrition is another common intervention, providing reliable access for overnight feeds that support growth and stabilize weight.
Lung Transplantation: In advanced CF lung disease characterized by severe airflow limitation, chronic respiratory failure, or refractory pulmonary hypertension, bilateral lung transplantation may be considered. Transplantation can prolong survival and improve symptoms but involves major surgery, lifelong immunosuppression, and new risks that must be carefully weighed against potential benefits.

Liver Transplantation and Combined Procedures: A minority of people develop advanced CF-related liver disease with portal hypertension or liver failure, for whom liver transplantation may be indicated. In some cases, combined liver–lung transplantation is considered when both organs are severely affected. These decisions require multidisciplinary assessment of prognosis, comorbidities, and patient goals.

Psychosocial and Supportive Care: Mental health, social support, and practical resources are integral to CF management. Chronic treatment demands, frequent clinic visits, hospitalizations, and uncertainties about future health can lead to anxiety, depression, or burnout for patients and families. Access to counseling, peer support, and social work services helps people integrate CF care into daily life and navigate schooling, employment, and family planning.

Longitudinal and Adaptive Care Planning: Across all of these domains, effective CF management is longitudinal, proactive, and adaptive. As new therapies, especially CFTR modulators, alter survival and disease patterns, treatment plans are continually revised so that airway clearance, medications, nutrition, and advanced interventions remain aligned with current needs and long-term goals. Regular reviews at CF centers ensure that care keeps pace with both evolving science and the lived realities of growing up and aging with cystic fibrosis.

Common Questions

Are people born with cystic fibrosis?

Cystic fibrosis is a genetic condition present from conception. The underlying CFTR gene variants are present in every cell from birth, even if symptoms are not obvious right away. Because the condition follows an autosomal recessive inheritance pattern, it often appears unexpectedly in families that did not know they carried CFTR variants.

Genetic Condition Present From Birth: Cystic fibrosis arises when a person inherits two disease-causing CFTR variants, one from each biological parent. These variants alter the CFTR protein that regulates salt and water movement across cell membranes, and the resulting dysfunction affects multiple organs over time.

Autosomal Recessive Inheritance Pattern: CF follows an autosomal recessive pattern, which means that both copies of the CFTR gene must carry disease-causing variants for a person to develop cystic fibrosis. Having one normal copy and one altered copy is usually enough to maintain sufficient CFTR function and prevent classic CF symptoms.

Carrier Parents Without Symptoms: Parents who each carry one CFTR variant are typically healthy and unaware of their carrier status. They are called carriers because they can pass the variant to their children without having cystic fibrosis themselves. Routine health care does not usually reveal carrier status unless specific genetic testing is performed.

Inheritance Probabilities For Each Pregnancy: When both parents are CFTR carriers, each pregnancy has the same pattern of probabilities: a 25% chance the child will inherit two variants and have CF, a 50% chance the child will inherit one variant and be an asymptomatic carrier, and a 25% chance the child will inherit two typical CFTR copies and neither have CF nor be a carrier. These chances reset with each pregnancy and do not depend on outcomes in previous pregnancies.

Silent Carrier Status in Families: Many families have no known history of cystic fibrosis before a child is diagnosed. This happens because CFTR carrier status is silent and can persist across generations without causing symptoms. In the United States, it is estimated that roughly 1 in 31 people are CFTR carriers without knowing it, which explains why CF can appear in families with no prior diagnosis.

Adult Onset

Can adults acquire cystic fibrosis over time?

Cystic fibrosis itself cannot be acquired in adulthood. The CFTR gene variants that cause CF are present from birth and do not arise later in life in the way that some cancers or infections do. However, not everyone with CF is diagnosed in infancy or childhood, particularly when gene variants preserve partial CFTR function or symptoms are mild or organ-limited.

Fixed CFTR Genotype From Birth: People are born with their CFTR genotype, including any disease-causing variants. Cystic fibrosis reflects the long-term consequences of these inherited variants rather than an exposure or event that occurs in adulthood. While new health problems can emerge over time, the underlying CFTR changes are present from the start.

Delayed Diagnosis in Milder Disease: Some individuals have milder CFTR variants that leave partial CFTR function intact. They may have fewer symptoms in early childhood or problems that are subtle enough to escape notice. In these cases, significant manifestations of CF may not become apparent until adolescence or adulthood, even though the condition has been present all along.
Organ-Limited or Atypical Presentations: A subset of people have symptoms confined largely to one organ system, such as chronic sinusitis, recurrent bronchitis with relatively preserved lung function, or recurrent pancreatitis. Because these presentations resemble more common conditions, they are often treated symptom by symptom for years without CF being considered.
Triggers for Adult Diagnosis: In adults, the diagnosis of cystic fibrosis is often made after repeated respiratory infections, long-standing sinus disease, unexplained pancreatitis, fertility problems, or a family member’s diagnosis prompts targeted testing. Sweat chloride testing and CFTR genetic analysis then confirm that CFTR dysfunction has been present since birth, even if the clinical label of CF is applied only later in life.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider regarding any questions you may have about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.